This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Top-Ranked ETFs & Stocks to Buy From Bargain Industries
by Sweta Killa
Given recovering fundamentals, investors should take advantage of the beaten-down prices. For them, we have highlighted four solid ETF & stock picks each from the industries that are currently undervalued and have a solid Zacks Rank.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Pharma ETFs Gain on Healthy Q4 Earnings
by Sweta Killa
Strong results led to solid trading in pharma ETFs over the past week.
Sector ETFs & Stocks to Gain/Lose on Coronavirus Outbreak
by Sanghamitra Saha
These sectors are directly related to the outbreak of Coronavirus in China in a positive or negative way,putting the spotlight on these ETFs and stocks.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
Pharma Sector Tops in October: Best ETFs & Stocks
by Sanghamitra Saha
Pharma sector wins in October, making these ETFs and stocks winners.
Pharma ETFs Set to Benefit Post Strong Q3 Earnings
by Sweta Killa
Robust results led to solid trading in pharma ETFs in a month.
Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?
by Sweta Killa
Despite robust results, pharma ETFs have been trending downward in a month.
AbbVie to Buy Allergan: Prescribed ETFs
by Sweta Killa
AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.